EGFR and non-small cell lung carcinoma: These studies in mice were prompted by the fact that gefitinib, which is an inhibitor of the epidermal growth factor receptor and used to treat non-small cell lung cancer in humans, has significant adverse side effects in therapy, such as respiratory dysfunction, which in part has been attributed to the fact the gefitinib also inhibits GAK[72].